Germain, Andrew R.Carmody, Leigh C.Morgan, BarbaraFernandez, CristinaForbeck, ErinLewis, Timothy A.Nag, Partha P.Ting, AmalVerPlank, LynnFeng, YuxiongPerez, Jose R.Dandapani, SivaramanPalmer, MichelleLander, EricGupta, Piyush B.Schreiber, StuartMunoz, Benito2014-08-142012Germain, Andrew R., Leigh C. Carmody, Barbara Morgan, Cristina Fernandez, Erin Forbeck, Timothy A. Lewis, Partha P. Nag, et al. 2012. “Identification of a Selective Small Molecule Inhibitor of Breast Cancer Stem Cells.” Bioorganic & Medicinal Chemistry Letters 22 (10) (May): 3571–3574. doi:10.1016/j.bmcl.2012.01.035. http://dx.doi.org/10.1016/j.bmcl.2012.01.035.0960-894Xhttp://nrs.harvard.edu/urn-3:HUL.InstRepos:12719983A high-throughput screen (HTS) with the National Institute of Health–Molecular Libraries Small Molecule Repository (NIH–MLSMR) compound collection identified a class of acyl hydrazones to be selectively lethal to breast cancer stem cell (CSC) enriched populations. Medicinal chemistry efforts were undertaken to optimize potency and selectivity of this class of compounds. The optimized compound was declared as a probe (ML239) with the NIH Molecular Libraries Program and displayed greater than 20-fold selective inhibition of the breast CSC-like cell line (HMLE_sh_Ecad) over the isogenic control line (HMLE_sh_GFP).en-UScancer stem cellsbreast cancerJournal Article2014-08-07Andrew R. Germain, Leigh C. Carmody, Barbara Morgan, Erin Forbeck, Cristina Fernandez, Timothy A. Lewis, Partha P. Nag, Amal Ting, Lynn VerPlank, Yuxiong Feng, Eric S. Lander, Piyush B. Gupta, Jose R. Perez, Sivaraman Dandapani, Michelle Palmer, Stuart L. Schreiber, Benito Munoz10.1016/j.bmcl.2012.01.035